2022 kicks off with key FDA decisions for Roche, Novartis and Pfizer, while Astrazeneca hopes to extend Lynparza even further.
November approval decisions loom for cilta-cel and Voxzogo, while molnupiravir heads for an advisory panel.
But a lacklustre pipeline could stoke the need for deals.
Altimmune’s early-stage obesity hit is impressive, but big pharma has more advanced rivals.
Investors are homing in on biopharma companies able to make real contributions to the coronavirus pandemic, but market frothiness is far from over.
Shares in the company surge after its weekly growth hormone treatment proves superior to daily injections, raising broader hopes for Ascendis’s long-acting technology.
Deals were a major driver of mid-cap share movement in the first quarter, but pipeline progress and misfires played their parts too.